Chemomab Therapeutics Ltd Stock Performance
| CMMB Stock | USD 1.80 0.08 4.26% |
The firm shows a Beta (market volatility) of 1.52, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Chemomab Therapeutics will likely underperform. At this point, Chemomab Therapeutics has a negative expected return of -0.48%. Please make sure to confirm Chemomab Therapeutics' potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if Chemomab Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Chemomab Therapeutics Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:4 | Last Split Date 2025-08-26 |
1 | Published on 2025-10-20 191237 - nchmf.gov.vn | 10/20/2025 |
2 | SNYs Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study | 10/22/2025 |
3 | Acquisition by Nicaise Claude of 11884 shares of Chemomab Therapeutics at 27.26 subject to Rule 16b-3 | 10/27/2025 |
4 | Chemomab Announces Multiple Presentations at AASLD The Liver Meeting 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholang... | 11/06/2025 |
5 | Will Chemomab Therapeutics Ltd. stock announce special dividend - July 2025 WrapUp Daily Profit Focused Stock Screening - newser.com | 11/14/2025 |
6 | How Chemomab Therapeutics Ltd. stock benefits from digital adoption - newser.com | 11/19/2025 |
7 | Chemomab to Participate in Oppenheimers Movers in Rare Disease Summit | 11/24/2025 |
8 | Chemomab Therapeutics Advances Nebokitug Phase 3 Trial with Regulatory Support - MSN | 12/12/2025 |
| Begin Period Cash Flow | 9.4 M | |
| Total Cashflows From Investing Activities | 2.3 M |
Chemomab Therapeutics Relative Risk vs. Return Landscape
If you would invest 265.00 in Chemomab Therapeutics Ltd on September 29, 2025 and sell it today you would lose (85.00) from holding Chemomab Therapeutics Ltd or give up 32.08% of portfolio value over 90 days. Chemomab Therapeutics Ltd is currently does not generate positive expected returns and assumes 5.0357% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Chemomab, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Chemomab Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Chemomab Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Chemomab Therapeutics Ltd, and traders can use it to determine the average amount a Chemomab Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0957
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CMMB |
Based on monthly moving average Chemomab Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Chemomab Therapeutics by adding Chemomab Therapeutics to a well-diversified portfolio.
Chemomab Therapeutics Fundamentals Growth
Chemomab Stock prices reflect investors' perceptions of the future prospects and financial health of Chemomab Therapeutics, and Chemomab Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Chemomab Stock performance.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 1.02 M | ||||
| Shares Outstanding | 6.16 M | ||||
| Price To Book | 0.99 X | ||||
| EBITDA | (13.96 M) | ||||
| Net Income | (14.01 M) | ||||
| Cash And Equivalents | 51.72 M | ||||
| Cash Per Share | 4.53 X | ||||
| Total Debt | 324 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.48 X | ||||
| Book Value Per Share | 1.82 X | ||||
| Cash Flow From Operations | (15.46 M) | ||||
| Earnings Per Share | (1.44) X | ||||
| Market Capitalization | 11.08 M | ||||
| Total Asset | 16.96 M | ||||
| Retained Earnings | (102.62 M) | ||||
| Working Capital | 12.82 M | ||||
About Chemomab Therapeutics Performance
By analyzing Chemomab Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Chemomab Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Chemomab Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Chemomab Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -16.6 K | -15.8 K | |
| Return On Tangible Assets | (0.82) | (0.86) | |
| Return On Capital Employed | (1.07) | (1.02) | |
| Return On Assets | (0.82) | (0.86) | |
| Return On Equity | (1.03) | (0.98) |
Things to note about Chemomab Therapeutics performance evaluation
Checking the ongoing alerts about Chemomab Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Chemomab Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Chemomab Therapeutics generated a negative expected return over the last 90 days | |
| Chemomab Therapeutics has high historical volatility and very poor performance | |
| Chemomab Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (14.01 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Chemomab Therapeutics Ltd currently holds about 51.72 M in cash with (15.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Chemomab Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Roughly 14.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Chemomab Therapeutics Advances Nebokitug Phase 3 Trial with Regulatory Support - MSN |
- Analyzing Chemomab Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Chemomab Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Chemomab Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Chemomab Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Chemomab Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Chemomab Therapeutics' stock. These opinions can provide insight into Chemomab Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Chemomab Stock analysis
When running Chemomab Therapeutics' price analysis, check to measure Chemomab Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemomab Therapeutics is operating at the current time. Most of Chemomab Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chemomab Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chemomab Therapeutics' price. Additionally, you may evaluate how the addition of Chemomab Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |